Abstract: Disclosed are cis-acting regulatory elements from a KIM-1 gene. The elements can be used to direct the expression of operably linked sequences in renal tissue.

Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.

Abstract: A system and method of keeping records includes recording information and metadata associated with the information. The metadata is protected from changes. The information can be displayed to a second user for acknowledgement. Acknowledgement by the second user can also be recorded. The metadata can provide an audit trail for reviewing additions, deletions and changes to the records.

Abstract: The present invention relates to novel receptors in the TNF family. A novel receptor has been identified, referred to herein as TRAIN. The invention relates to DNA sequences encoding TRAIN receptors. The invention also contemplates recombinant DNAs comprising a sequence encoding TRAIN receptors or fragments thereof, as well as hosts with stably integrated TRAIN-R sequences introduced into their genome, or possessing episomal elements.

Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.

Abstract: Aqueous dispersion of a polyurethane, obtainable by reacting polyisocyanates and isocyanate-reactive compounds in miniemulsion, wherein the isocyanate-reactive compounds are at least in part polysiloxanes of the formula I where R1 and R2 independently of one another are a monovalent hydrocarbon radical having not more than 20 carbon atoms, which if appropriate may also contain heteroatoms such as O or N, R3 and R4 independently of one another are a single bond or a divalent hydrocarbon radical having not more than 20 carbon atoms, which if appropriate may also contain heteroatoms such as O or N, R5 and R6 independently of one another are a group OH, SH, NH2 or NHR7 and R7 is a monovalent hydrocarbon radical having not more than 20 carbon atoms, which if appropriate may also contain heteroatoms such as O or N, and n is an integer from 1 to 100.

Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.

Abstract: The present invention relates generally to the amplification of nucleic acids. More specifically, the present invention facilitates amplification of total RNA for a variety of purposes, including analysis utilizing nucleotide assays, constructing cDNA libraries, in situ hybridization, and TaqMan. Additionally, the present invention facilitates amplification of total RNA isolated from biological tissues.

Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.

Abstract: The disulfide bridges in a protein sequence can be described by a disulfide signature that includes information about cysteine spacing and disulfide topology. Proteins with similar disulfide signatures can be structurally similar despite low overall sequence homology. A database of disulfide signatures can be compiled from publicly available sequence data.

Abstract: Nucleic acid sequences encoding genes that are overexpressed by human ovarian cancers are provided. These genes and the corresponding antigens are useful diagnostic and therapeutic targets. The invention provides cancer therapies that target these antigens, especially using monoclonal antibodies that target the Anat-2 antigen.

Abstract: This invention relates to a nucleotide array containing polynucleotide probes complementary to, or fragments of, Cynomolgus monkey genes, and the use of such a nucleotide array to characterize the biological effects, including the actions, targets, and toxicities, of therapeutic agents in primates, e.g., a human, a Cynomolgus monkey, or a Rhesus monkey, in particular a nucleotide array to be used in identifying the toxicities of therapeutic agents administered to a non-human primate, e.g., a Cynomolgus monkey or a Rhesus monkey.

Abstract: Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.

Abstract: The invention provides methods for treating diseases involving aberrant amyloid-? (A?) peptide deposition, including Alzheimer's Disease, by the administration of Nogo receptor antagonists.

Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.

Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.

Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.

Abstract: The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.

Abstract: Disclosed are cis-acting regulatory elements from a KIM-1 gene. The elements can be used to direct the expression of operably linked sequences in renal tissue.

Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.